Conditions: Lymphoma Multiple Myeloma Leukemia Myelodysplastic Syndrome
Keywords: Acute lymphocytic leukemia (ALL) Acute myeloid leukemia (AML) Acute Leukemia Refractory or Relapsed AML Myelodysplastic syndrome (MDS) Chronic myeloid leukemia (CML) Chronic myelomonocytic leukemia Hodgkin's Lymphoma Non-Hodgkin's lymphoma Philadelphia-negative myeloproliferative disorder Hematologic Malignancies Transplantation Busulfan Fludarabine Cytoxan Bone Marrow Allogeneic Related donor unrelated donor
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 92
Healthy volunteers: no

Brief summary:
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.

Detailed description:
A person who has cancer of the blood or lymph glands can be treated by bone marrow transplantation (BMT). BMT has developed over several decades of research on both animal and human subjects as an effective treatment of various malignant and nonmalignant hematologic diseases. Many hematologic malignancies can be successfully treated with a combination of high-dose chemotherapy or chemo-radiotherapy and transplantation of allogeneic bone marrow or peripheral blood stem cells (alloBMT)

However, a possible side effect of BMT is graft versus host disease (GVHD). GVHD occurs when cells of the donor's immune system, which are present in the bone marrow, attack the BMT recipient's normal tissue. Prevention of GVHD is important for the success of the bone marrow transplant. This research is being done to find the most effective and least toxic way to prevent GVHD after BMT

Arms:

Interventions: intervention 1: Busulfan, Fludarabine, Cytoxan
Intervention descriptions: intervention 1: Busulfan once a day for 4 days

Fludarabine once a day for 4 days

Bone marrow transplant

Cytoxan two doses

Protocol document: